Loading stock data…
Odyssey Therapeutics, Inc. (ODTX)
$18.89+0.83 (+4.60%)
Market ClosedLast close Jun 29
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q4 2024 | Q3 2024 |
|---|---|---|
| Total Revenue | $1.75M | — |
| Gross Profit | — | — |
| Operating Income | -$37.12M | — |
| Net Income | -$35.93M | — |
Peer Comparison
JNJUNHPFE
Fundamentals
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, whic...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$806.21M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
9.39%
Volume
Today's trading volume
388,452
Recent News
Kardigan rises in Nasdaq debut after upsized $400 million IPO
June 18 () - Kardigan's shares rose 1.6% in their Nasdaq debut on Thursday, after the heart drug developer raised $400 million in an upsized U.
Healthcare IPOs Raise $4.7 Billion As Odyssey, Mobia Debuts Slip
Odyssey and Mobia raised a combined $454 million, but both healthcare companies traded lower in their Friday debuts.